Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12514MR)

This product GTTS-WQ12514MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12514MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8400MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ6195MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ7888MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-249320
GTTS-WQ6951MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ15592MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ6566MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ7586MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW